Hydromorphon | 845-68-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Hydromorphon
• 英文别名: Hymorphan (Salt/Mix)；9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
• CAS: 845-68-1
• 化学式: C₁₇H₁₉NO₃
• 分子量: 285.343
• InChiKey: WVLOADHCBXTIJK-UHFFFAOYSA-N

物化性质

• 沸点：
  475.6±45.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)
• 保留指数：
  2472;2460;2461.6;2467

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

代谢

氢吗啡酮是已知的人类对氢可酮的代谢产物。

Hydromorphone is a known human metabolite of hydrocodone.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  Hydromorphon 生成 (+/-)-dihydrocodeinone
  参考文献：
  名称：

  DE380919

  摘要：

  公开号：
• 作为产物：
  描述：

  吗啡 在 乙醇 、 钯 作用下， 生成 Hydromorphon
  参考文献：
  名称：

  Katada, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 92

  摘要：

  DOI：

文献信息

• Heterogeneous Ruthenium Metal Catalyst for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof
  申请人：GINDELBERGER David E.

  公开号：US20110071016A1

  公开（公告）日：2011-03-24

  The present disclosure generally relates to catalytic methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydrocodone, hydromorphone, or a derivative thereof, by means of a conversion or an isomerization of codeine, morphine, or a derivative thereof, respectively, using a heterogeneous ruthenium metal catalyst.

  本公开涉及一般用于生产阿片类衍生物的催化方法。更具体地，本公开涉及通过使用异质钌金属催化剂，通过对可待因、吗啡或其衍生物进行转化或异构化的方式，制备羟考酮、羟吗啡或其衍生物。
• Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof
  申请人：Orr Brian

  公开号：US20110071297A1

  公开（公告）日：2011-03-24

  The present disclosure generally relates to methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydromorphone, hydrocodone, or a derivative thereof, by means of a non-catalytic hydrogenation reaction of thebaine, oripavine or a derivative thereof, respectively, using a hydrazide reagent, followed by hydrolysis of the hydrogenated intermediate at a low temperature and for a short period of time. Additionally, the present disclosure relates to a composition comprising the desired hydromorphone, hydrocodone, or a derivative thereof, in combination with a 6-beta compound that is structurally related thereto.

  本公开涉及一般用于生产阿片类衍生物的方法。更具体地，本公开涉及通过非催化氢化反应分别使用肼酰肼试剂对吗啡碱、奥利帕碱或其衍生物进行制备羟吗啡、羟考酮或其衍生物，随后在低温下和短时间内对氢化中间体进行水解。此外，本公开还涉及一种包含所需的羟吗啡、羟考酮或其衍生物与结构相关的6-β化合物的组合物。
• PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS
  申请人：Jenkins Thomas E.

  公开号：US20090137618A1

  公开（公告）日：2009-05-28

  Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound.

  包含电子吸引基团的前药，在规范中定义，对于为患者提供经过给药后激活的、受控释放生物活性化合物的方法是有用的。
• Novel Therapeutic Compounds
  申请人：SESHA Ramesh

  公开号：US20120046272A1

  公开（公告）日：2012-02-23

  The present invention describes a series of therapeutically active compounds of formula I, X—Y—Z  (I) that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH 2 ) n —, —CO—, —CONR a —, —NR a CO—, —NR a COO—, —COO—, —CONR a CO—, —CONR a COO— and —COOCOO—. The compounds are useful to treat neurodegenerative disorders, depression, Alzheimer's disease, cognitive disorders, motor disorders, Parkinson's disease, drug addiction, behavioral disorders, inflammatory disorders, stomach disorders, cancers, acute pain, chronic pain and recurrent pain.

  本发明描述了一系列具有治疗活性的化合物，其化学式为I，X—Y—Z  (I)，适用于治疗哺乳动物中的某种疾病。在化学式I中，X和Z，可以相同也可以不同，独立地选择自取代或未取代的烷基、取代或未取代的烯基、取代或未取代的环烷基、取代或未取代的环烷基烷基、取代或未取代的芳基、取代或未取代的芳基烷基、取代或未取代的杂芳基、取代或未取代的杂芳基烷基、取代或未取代的杂环基团或取代或未取代的杂环烷基；Y是从—O—、—S—、—NH—、—(CH2)n—、—CO—、—CONRa—、—NRaCO—、—NRaCOO—、—COO—、—CONRaCO—、—CONRaCOO—和—COOCOO—中选择的连接基团。这些化合物适用于治疗神经退行性疾病、抑郁症、阿尔茨海默病、认知障碍、运动障碍、帕金森病、药物成瘾、行为障碍、炎症性疾病、胃病、癌症、急性疼痛、慢性疼痛和复发性疼痛。
• Preparation of 6-Alpha-Amino N-Substituted Morphinans by Catalytic Hydrogen Transfer
  申请人：Grote Christopher W.

  公开号：US20100317683A1

  公开（公告）日：2010-12-16

  The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer.

  本发明提供了用于立体选择性合成6-α-氨基N-取代吗啡酮类化合物的方法。具体来说，该发明提供了通过催化氢转移的还原胺化反应合成6-酮N-取代吗啡酮类化合物的方法。

表征谱图